🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsVendor Reviews[REVIEW] GL Biochem — compounded tirzepatide quality report

[REVIEW] GL Biochem — compounded tirzepatide quality report

COA_Karl Thu, Jun 4, 2026 at 1:39 PM 6 replies 271 viewsPage 1 of 2
COA_Karl
Senior Member
2,123
8,901
Jan 2024
Pennsylvania
Jun 4, 2026 at 1:39 PM#1

My pharmacy stopped supplying with three weeks notice and a letter that explained nothing, so I went and read the statute.

Reporting this the way I would want to read it: what I did, what it cost, what I can actually verify.

Two things anyone can check: a state licence number for a 503A, and an FDA outsourcing-facility registration for a 503B. Both are publicly searchable, and a pharmacy unwilling to give you either has answered the question.

The enforcement dates were staggered by category — 503A first, 503B a few weeks later — because outsourcing facilities have manufactured inventory and clinic contracts to unwind while a 503A makes to order.

The narrow version of the question is what actually distinguishes 503A from 503B, in terms of what each may make and from what starting material. I have searched first, so if this is covered somewhere point me at it and I will read it.

31 1matt_MKE, Dr.ReproEndo, lucas_SP_BR and 28 others
Reply Quote Save Share Report
LipidDoc_ATL
Senior Member
1,123
5,678
Apr 2024
Atlanta, GA
Jun 4, 2026 at 2:40 PM#2
COA_Karl said:
My pharmacy stopped supplying with three weeks notice and a letter that explained nothing, so I went and read the statute.

COA_Karl has the substance of this right. The condition it depends on is worth stating. Resolution therefore closed the doors unevenly, and the asymmetry follows from the bulks lists. For 503B the shortage clause was the only route to these molecules, so that route shut completely. A 503A pharmacy can still argue a doorway via "component of an approved drug" — but only for the substance in the form present in the approved product, which is exactly where the base-versus-salt argument lives, and it does nothing about the copy restriction, which came back into force on resolution.

Last edited: Jun 4, 2026 at 7:40 PM
30 0traveltech_sara, AttorneyGrant, DebRD_ATL and 27 others
Reply Quote Save Share Report
TrialNerd_Beth
Senior Member
2,345
11,234
Jan 2024
Bethesda, MD
Jun 4, 2026 at 3:41 PM#3
COA_Karl said:
My pharmacy stopped supplying with three weeks notice and a letter that explained nothing, so I went and read the statute.

This is where I part company with the consensus forming above. A research-chemical supplier selling lyophilised powder labelled research use only is not compounding and is not claiming to. It is a different legal universe with no pharmacy oversight, no patient relationship and no content guarantee, and conflating the two in these threads helps nobody.

Correct me if the detail matters more than I have assumed.

29 24TomTeleRx, DoseLogDan, SleepFixSam and 26 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
PharmD_Rodriguez
Senior Member
3,456
14,567
Jan 2024
Miami, FL
Jun 4, 2026 at 4:42 PM#4

Answering the narrow version, because the broad one does not have a single answer. The shortage clause is the answer to the second question and it is a subtraction rather than an addition. Both exemptions forbid compounding something that is essentially a copy of a commercially available approved product. A product FDA has listed as in shortage is not treated as commercially available, so listing removed the objection that otherwise blocked compounding. It never created a permission; it withdrew a prohibition, which is why it evaporated the moment the supply fact changed.

28 23dan_philly, MeganSA_TX, LarryQC_SD and 25 others
Reply Quote Save Share Report
mona_PHX
Member
189
890
Dec 2024
Phoenix, AZ
Jun 4, 2026 at 10:29 PM#5
LipidDoc_ATL said:
Resolution therefore closed the doors unevenly, and the asymmetry follows from the bulks lists.

Agreed, with a caveat about community reputation: it is a lagging indicator. Reports arrive weeks after orders, so a supplier can look excellent for a month after quality has already changed.

Ask again with the specifics and you will get a better answer than this one.

27 22MariaRD, AussieAnna, BethLabQueen and 24 others
Reply Quote Save Share Report

Similar Threads

[REVIEW] WWB — 8 months, 6 orders, all Janoshik tested7 replies
[REVIEW] QSC — consistency and pricing, 10+ orders deep5 replies
[REVIEW] GGPeps — 6 orders, all independently tested3 replies
Which vendor should I go with? Side-by-side comparison3 replies
How do you vet a new vendor? My quality checklist9 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register